Miraculins Signs Letter of Intent for PreVu(R) Distribution in India With $4 Million USD in Minimum Sales Revenues Projected ...

Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical
diagnostic company focused on acquiring, developing and commercializing
diagnostic tests and risk assessment technologies for unmet clinical needs,
today announces that it has executed a Letter of Intent ("LOI") with Citizen
Doctor Pvt. Ltd. ("CDPL"), an Indian healthcare services company, to appoint
CDPL as the exclusive distributor for the PreVu(R) Non-invasive Skin Cholesterol
Point-of-Care (POC) Test in India. The LOI also provides for the assignment of
non-exclusive distribution rights for PreVu(R) POC to CDPL in certain other
Asian countries. 


The non-binding LOI has established the principal terms and conditions of the
proposed distribution agreement (the "Agreement") between Miraculins and CDPL,
exclusively for India and non-exclusively for certain other Asian countries,
including PreVu(R) POC Spectrophotometer and Reagent Kit pricing, upfront and
milestone payments, product ordering and diligence requirements, and ongoing
responsibilities of the parties. In addition, CDPL would place a guaranteed
first order for 20,000 PreVu(R) POC tests on signing of the Agreement, which
would be activated upon Indian regulatory clearance. The LOI provides the
parties with a period of 90 days within which to finalize definitive
documentation for the Agreement. 


The term of the Agreement would extend for five years from the date of Indian
regulatory clearance, subject to minimum annual order quantities by CDPL. If
minimum orders were met, this would represent a total order value of
approximately $4 Million USD in projected PreVu(R) Spectrophotometer and Reagent
Kit sales over the length of the term. Miraculins would be responsible for
leading the Indian regulatory clearance process, with its related costs being
the responsibility of CDPL. Guidance and support for the regulatory process
would be provided by CDPL as necessary. 


With India being a country that relies heavily on predicate country regulatory
clearances as regards healthcare products, it is anticipated that the regulatory
clearances PreVu(R) POC has already received in Canada, the European Union, and
the U.S., will be advantageous to the process.  


Upon clearance of the PreVu(R) POC in India, CDPL would be responsible for all
sales and marketing costs. Miraculins would provide sales and marketing guidance
and training support as required. Miraculins would retain the right to establish
programs for ongoing device servicing and maintenance once the PreVu(R) POC
devices begin to be sold into the field. 


"This is a very important development in the continuing effort to establish
PreVu(R) POC as a new clinical tool to assist with coronary artery disease risk
assessment worldwide," stated Paul Moreau, Vice-President, Sales and Marketing
for Miraculins. "CDPL is changing how risk assessment is delivered throughout
India, and the recognition of PreVu's value by medical professionals in that
country where cardiovascular disease is a leading killer, is extremely
significant". 


According to the World Health Organization, cardiovascular diseases will be the
largest cause of death and disability in India by 2020. India has a present
population of 1.237 billion.


About Citizen Doctor Pvt. Ltd. 

Citizen Doctor Pvt. Ltd. operates Checkitsa, an Indian healthcare company
headquartered in Hyderabad that is revolutionizing the way risk assessment and
ongoing monitoring of disease conditions is delivered throughout the country.
Checkitsa leverages new generation e-health medical devices, products and
services based on internet, wireless, mobile and Bluetooth technology. The
company advocates a shift away from acute care to preventative care that
promotes awareness of personal health risks, enabling patients to assess,
monitor and manage their health anytime, anywhere, under the supervision and
guidance of medical experts. Checkitsa services are designed to work around a
patient's schedule and preferences and are predominantly delivered outside of
hospital and clinical settings including in the home, the office or workplace,
at neighbourhood pharmacies, as well as at shopping malls. Checkitsa Workplace
is India's first and the only on-site, end-to-end workplace wellness program
that converts company wellness strategies into an "Organizational Human
Performance Strategy", with guaranteed health risk reduction of individual
employees and improvement of the overall health status of a company. Management
behind Citizen Doctor Pvt. Ltd have been involved in direct-to-consumer health
care initiatives for over ten years in the Indian market and were responsible
for starting one of the first corporate chains of hospitals in the country,
taking that company to a successful IPO. Management has also been involved in
drafting many medical and healthcare laws in India. For more information visit
www.checkitsa.com. 


About Miraculins 

Miraculins is a medical diagnostic company focused on acquiring, developing and
commercializing non-invasive technologies for unmet clinical needs. The
Company's Scout DS(R) system is the first non-invasive diabetes testing system
designed to provide a highly sensitive and convenient method for measuring
diabetes related biomarkers in the skin, the accumulation of which are
accelerated by abnormal blood sugar levels and oxidative stress. Unlike current
testing methods, a Scout DS(R) test requires no blood draw, no fasting, and no
waiting for a lab result. The product has been used and validated in thousands
of patients around the world. The Company's PreVu(R) POC Test is a revolutionary
new coronary artery disease risk assessment technology that measures cholesterol
levels in a patient's skin non-invasively, painlessly and without the need for
fasting. For more information visit www.miraculins.com.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements include statements regarding the completion of definitive
documentation and the execution of the Agreement, the receipt of Indian
regulatory clearance, and the impact of the Agreement on the Company. These
forward-looking statements relate to, among other things, our objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and outlook,
including, without limitation, our anticipated future operating results, and
can, in some cases, be identified by the use of words such as "believe,"
"anticipate," "expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations, projections
or other characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Miraculins' early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Miraculins' filings with Canadian securities regulatory
authorities, as well as Miraculins' ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release. Miraculins cautions
that the foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking statements to make
decisions with respect to Miraculins investors and others should carefully
consider the foregoing factors and other uncertainties and potential events. 


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Miraculins
cannot provide assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to update or
revise any forward-looking statements. 


PreVu(R) and Scout DS(R) are registered trademarks of Miraculins Inc. All Rights
Reserved. 2014.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
[e-mail]
www.miraculins.com